Prosetta Antiviral Inc Enters into Multi-year Antiviral Drug Development Collaboration with Bristol-Myers Squibb
Prosetta Antiviral Inc.Thomas Higgins, 415-346-8866 ext. 225
Prosetta Antiviral Inc today announced the execution of a strategic alliance with Bristol-Myers Squibb Company (NYSE: BMY) to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.
Prosetta currently has a portfolio comprising novel chemical classes of small molecules with robust antiviral activity which target catalytic host protein interactions essential for the virus, but not the host. These molecules represent a new therapeutic approach for antiviral agents.
The collaboration will include a research program focused on the discovery and advancement of compounds shown to block viral capsid assembly using Prosetta’s proprietary drug discovery platform. Bristol-Myers Squibb will have the right to develop and commercialize products arising from the research program.
Prosetta will receive an upfront payment and multi-year research funding. Prosetta is eligible to receive milestone payments and royalties based on worldwide sales of the drugs emerging from the collaboration.
Vishwanath R. Lingappa, MD, PhD, Prosetta’s Chief Technology Officer and Co-CEO, stated, “We greatly value this opportunity to collaborate with Bristol-Myers Squibb scientists in a joint program dedicated to a completely new approach to protecting human health against viral infections.”
Prosetta is a 9-year-old San Francisco-based biotechnology company with an innovative approach to drug discovery. The Prosetta platform emerged from 25 years of basic research on cell-free protein synthesizing systems (CFPSS) which validated CFPSS as an effective tool for approaching physiologically important protein-protein interactions, including host-virus interactions, in ways not previously attempted. Prosetta was founded to explore the potential of these tools, and the ground-breaking conceptual framework they made possible for drug discovery. Specifically, Prosetta’s proprietary CFPSS allows detection of highly druggable protein-protein interactions that have not previously been identified.